Abstract | BACKGROUND: CASE PRESENTATION: CONCLUSIONS: Increased awareness, prompt recognition, and aggressive treatments are likely the best opportunity for improved outcomes in this severe side effect.
|
Authors | Safa Abdelhakim, Jonah D Klapholz, Bhaskar Roy, Sarah A Weiss, Declan McGuone, Zachary A Corbin |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 16
Issue 1
Pg. 81
(Feb 24 2022)
ISSN: 1752-1947 [Electronic] England |
PMID | 35197122
(Publication Type: Case Reports, Journal Article)
|
Copyright | © 2022. The Author(s). |
Chemical References |
- Immune Checkpoint Inhibitors
- Ipilimumab
|
Topics |
- Aged, 80 and over
- Female
- Humans
- Immune Checkpoint Inhibitors
- Ipilimumab
(adverse effects)
- Mononeuropathies
(chemically induced, drug therapy)
- Neoplasm Recurrence, Local
(drug therapy)
- Nervous System Diseases
(chemically induced)
|